ArticleScientific reports2018
A multiplex serologic platform for diagnosis of tick-borne diseases.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Development and Evaluation of a Dual-Target One-Step Nested PCR for the Detection of Spotted Fever GroupPathogens (Basel, Switzerland) · 2026Article
- Evaluation of immunoreactive epitopes in the sera and cerebrospinal fluid of patients with post-treatment Lyme disease syndrome.Scientific reports · 2026Article
- Epidemiology and risk analysis of Powassan virus infection, New York state, USA, 2013-2023.Epidemiology and infection · 2026Article
- Diagnostic and Therapeutic Challenges in Lyme Disease and Co-Infections: Unraveling Neuropsychiatric and Neurological Complexities-A Comprehensive Case Series Analysis.Integrative medicine (Encinitas, Calif.) · 2025Article
- A type-specific B-cell epitope at the apex of outer surface protein C (OspC) of the Lyme disease spirochete,Microbiology spectrum · 2025Article
- A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases.Scientific reports · 2025Article
- Germline encoded residues dominate the interaction of a human monoclonal antibody with decorin binding protein A ofFrontiers in immunology · 2025Article
- Proposed research classification criteria for Lyme disease in infection associated chronic illness studies.Frontiers in medicine · 2025Article
- Identification of Schistosoma haematobium and Schistosoma mansoni linear B-cell epitopes with diagnostic potential using in silico immunoinformatic tools and peptide microarray technology.PLoS neglected tropical diseases · 2024Article
- Identification ofInfection and immunity · 2024Article
- Human antibodies in Mexico and Brazil neutralizing tick-borne flaviviruses.Cell reports · 2024Article
- Pathogen Discovery in the Post-COVID Era.Pathogens (Basel, Switzerland) · 2024Review
- A Refined Human Linear B Cell Epitope Map of Outer Surface Protein C (OspC) From the Lyme Disease Spirochete,Pathogens & immunity · 2024Article
- Tick exposure biomarkers: A One Health approach to new tick surveillance tools.Current research in parasitology & vector-borne diseases · 2024Article
- Tick-Borne Co-Infections: Challenges in Molecular and Serologic Diagnoses.Pathogens (Basel, Switzerland) · 2023Review
- Epitope Mapping of BmpA and BBK32ACS infectious diseases · 2023Article
- What a Tick Can Tell a Doctor: Using the Human-Biting Tick in the Clinical Management of Tick-Borne Disease.Journal of clinical medicine · 2023Article
- From Tick to Test: A Comprehensive Review of Tick-Borne Disease Diagnostics and Surveillance Methods in the United States.Life (Basel, Switzerland) · 2023Review
- Modeling the sequence dependence of differential antibody binding in the immune response to infectious disease.PLoS computational biology · 2023Article
- Antibody Immunity to Zika Virus among Young Children in a Flavivirus-Endemic Area in Nicaragua.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Tick-borne diseases are the most common vector-borne diseases in the United States, with serology being the primary method of diagnosis. We developed the first multiplex, array-based assay for serodiagnosis of tick-borne diseases called the TBD-Serochip. The TBD-Serochip was designed to discriminate antibody responses to 8 major tick-borne pathogens present in the United States, including Anaplasma phagocytophilum, Babesia microti, Borrelia burgdorferi, Borrelia miyamotoi, Ehrlichia chaffeensis, Rickettsia rickettsii, Heartland virus and Powassan virus. Each assay contains approximately 170,000 12-mer linear peptides that tile along the protein sequence of the major antigens from each agent with 11 amino acid overlap. This permits accurate identification of a wide range of specific immunodominant IgG and IgM epitopes that can then be used to enhance diagnostic accuracy and integrate differential diagnosis into a single assay. To test the performance of the TBD-Serochip, we examined sera from patients with confirmed Lyme disease, babesiosis, anaplasmosis, and Powassan virus disease. We identified a wide range of specific discriminatory epitopes that facilitated accurate diagnosis of each disease. We also identified previously undiagnosed infections. Our results indicate that the TBD-Serochip is a promising tool for a differential diagnosis not available with currently employed serologic assays for TBDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.